Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2b Randomized, Double-Blind, Placebo-Controlled Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

NCT07220811 is registered in ClinicalTrials.gov with RAPT Therapeutics, Inc. as lead sponsor.

NCT NCT07220811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07220811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2b Randomized, Double-Blind, Placebo-Controlled Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
Lead sponsor
RAPT Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
October 22, 2025
Completion date
January 31, 2028
Enrollment
100 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

ig-e mediated food allergy